The present invention relates to a vascular-hyperpermeability-inhibiting amount of a compound selected from danazol and pharmaceutically acceptable salts of danazol, for use in treating a disease or condition mediated by vascular hyperpermeability in an animal in need thereof, wherein the disease or condition is diabetes.